Abela, J. E., Going, J. J., Mackenzie, J. F., McKernan, M., O'Mahoney, S., & Stuart, R. C. (2008). Systematic four-quadrant biopsy detects Barrett's dysplasia in more patients than nonsystematic biopsy. Am J Gastroenterol., 103(4), 850-855.
Agilent Technologies. (2018). PD-L1 IHC 22C3 pharmDx: Interpretation Manual – NSCLC. Santa Clara: Agilent Technologies. Hentet fra https://www.agilent.com/cs/library/usermanuals/public/29158_pd-l1-ihc-22C3-pharmdx-nsclc-interpretation-manual.pdf
Agilent Technologies. (2019). PD-L1 IHC 22C3 pharmDx Interpretation Manual – NSCLC: for in Vitro diagnostic use. Santa Clara: Agilent Technologies. Hentet fra https://www.agilent.com/cs/library/usermanuals/public/29158_pd-l1-ihc-22C3-pharmdx-nsclc-interpretation-manual.pdf
Al-Batran, S.-E., Homann, N., Pauligk, C., Goetze, T. O., Meiler, J., Kasper, S., Kopp, H.-G., Mayer, F., Haag, G. M., Luley, K., Lindig, U., Schmiegel, W., Pohl, M., Stoehlmacher, J., Folprecht, G., Probst, S., Prasnikar, N., Fischbach, W., Mahlberg, R., Trojan, J., Koenigsmann, M., Martens, U. M., Thuss-Patience, P., Egger, M., Block, A., Heinemann, V., Illerhaus, G., Moehler, M., Schenk, M., Kullmann, F., Behringer, D. M., Heike, M., Pink, D., Teschendorf, C., Löhr, C., Bernhard, H., Schuch, G., Rethwisch, V., von Weikersthal, L. F., Hartmann, J. T., Kneba, M., Daum, S., Schulmann, K., Weniger, J., Belle, S., Gaiser, T., Oduncu, F. S., Güntner, M., Hozaeel, W., Reichart, A., Jäger, E., Kraus, T., Mönig, S., Bechstein, W. O., Schuler, M., Schmalenberg, H., Hofheinz, R. D., & Investigators, F. A. (2019). Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet, 393(10184), 1948-1957. https://doi.org/10.1016/S0140-6736(18)32557-1
Al-Batran, S.-E., Homann, N., Schmalenberg, H., Kopp, H.-G., Haag, G. M., Luley, K. B., Schmiegel, W. H., Folprecht, G., Probst, S., Prasnikar, N., Thuss-Patience, P. C., Fischbach, W., Trojan, J., Koenigsmann, M., Pauligk, C., Goetze, T. O., Jaeger, E., Meiler, J., Schuler, M. H., & Hofheinz, R. (2017). Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35(15_suppl), 4004. https://doi.org/10.1200/JCO.2017.35.15_suppl.4004
Al-Batran, S. E., Hartmann, J. T., Hofheinz, R., Homann, N., Rethwisch, V., Probst, S., Stoehlmacher, J., Clemens, M. R., Mahlberg, R., Fritz, M., Seipelt, G., Sievert, M., Pauligk, C., Atmaca, A., & Jäger, E. (2008). Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 19(11), 1882-1887. https://doi.org/10.1093/annonc/mdn403
Allum, W. H., Blazeby, J. M., Griffin, S. M., Cunningham, D., Jankowski, J. A., Wong, R., Association of Upper Gastrointestinal Surgeons of Great, B., Ireland, t. B. S. o. G., & the British Association of Surgical, O. (2011). Guidelines for the management of oesophageal and gastric cancer. Gut, 60(11), 1449-1472.
Allum, W. H., Stenning, S. P., Bancewicz, J., Clark, P. I., & Langley, R. E. (2009). Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27(30), 5062-5067. https://doi.org/10.1200/jco.2009.22.2083
Ba-Ssalamah, A., Matzek, W., Baroud, S., Bastati, N., Zacherl, J., Schoppmann, S. F., Hejna, M., Wrba, F., Weber, M., Herold, C. J., & Gore, R. M. (2011). Accuracy of hydro-multidetector row CT in the local T staging of oesophageal cancer compared to postoperative histopathological results. Eur Radiol, 21(11), 2326-2335. https://doi.org/10.1007/s00330-011-2187-2
Bang, Y. J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., Aprile, G., Kulikov, E., Hill, J., Lehle, M., Ruschoff, J., & Kang, Y. K. (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 376(9742), 687-697. https://doi.org/10.1016/s0140-6736(10)61121-x
Barbour, A. P., Rizk, N. P., Gonen, M., Tang, L., Bains, M. S., Rusch, V. W., Coit, D. G., & Brennan, M. F. (2007). Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome. Ann Surg., 246(1), 1-8. https://doi.org/10.1097/01.sla.0000255563.65157.d2
Bedenne, L., Michel, P., Bouche, O., Milan, C., Mariette, C., Conroy, T., Pezet, D., Roullet, B., Seitz, J. F., Herr, J. P., Paillot, B., Arveux, P., Bonnetain, F., & Binquet, C. (2007). Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25(10), 1160-1168. https://doi.org/10.1200/jco.2005.04.7118
Bergquist, H., Wenger, U., Johnsson, E., Nyman, J., Ejnell, H., Hammerlid, E., Lundell, L., & Ruth, M. (2005). Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial. Dis.Esophagus., 18(3), 131-139.
Biere, S. S., van Berge Henegouwen, M. I., Maas, K. W., Bonavina, L., Rosman, C., Garcia, J. R., Gisbertz, S. S., Klinkenbijl, J. H., Hollmann, M. W., de Lange, E. S., Bonjer, H. J., van der Peet, D. L., & Cuesta, M. A. (2012). Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet, 379(9829), 1887-1892. https://doi.org/10.1016/s0140-6736(12)60516-9
Bosman, F. T., Carneiro, F., Hruban, R. H., & Theise, N. D. (red.). (2010). WHO Classification of Tumours of the Digestive System (4. utg.). (WHO Classification of Tumours Volume 3). Lyon: IARC.
Bozzetti, F. (2010). Nutritional support in patients with oesophageal cancer. Support Care Cancer, 18(Suppl 2), 41-50.
Braga, M., Ljungqvist, O., Soeters, P., Fearon, K., Weimann, A., & Bozzetti, F. (2009). ESPEN Guidelines on Parenteral Nutrition: surgery. Clin Nutr., 28(4), 378-386.
Brierley, J., Gospodarwicz, M. K., & Wittekind, C. (2017). TNM classification of malignant tumours (8. utg.). Chichester: John Wiley & Sons.
Bruzzi, J. F., Munden, R. F., Truong, M. T., Marom, E. M., Sabloff, B. S., Gladish, G. W., Iyer, R. B., Pan, T. S., Macapinlac, H. A., & Erasmus, J. J. (2007). PET/CT of esophageal cancer: its role in clinical management. Radiographics : a review publication of the Radiological Society of North America, Inc, 27(6), 1635-1652. https://doi.org/10.1148/rg.276065742
Burgart, L. J., Chopp, W. V., & Jain, D. (2021). Protocol for the Examination of Specimens From Patients With Carcinoma of the Esophagus (Version 4.2.0.0 utg.). College of American Pathologists (CAP).
Burmeister, B. H., Dickie, G., Smithers, B. M., Hodge, R., & Morton, K. (2000). Thirty-four patients with carcinoma of the cervical esophagus treated with chemoradiation therapy. Archives of otolaryngology--head & neck surgery, 126(2), 205-208.
Burmeister, B. H., Thomas, J. M., Burmeister, E. A., Walpole, E. T., Harvey, J. A., Thomson, D. B., Barbour, A. P., Gotley, D. C., & Smithers, B. M. (2011). Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. European journal of cancer (Oxford, England : 1990), 47(3), 354-360. https://doi.org/10.1016/j.ejca.2010.09.009
Cancer Genome Atlas Research, N., Analysis Working Group: Asan, U., Agency, B. C. C., Brigham, Women’s, H., Broad, I., Brown, U., Case Western Reserve, U., Dana-Farber Cancer, I., Duke, U., Greater Poland Cancer, C., Harvard Medical, S., Institute for Systems, B., Leuven, K. U., Mayo, C., Memorial Sloan Kettering Cancer, C., National Cancer, I., Nationwide Children’s, H., Stanford, U., University of, A., University of, M., University of North, C., University of, P., University of, R., University of Southern, C., University of Texas, M. D. A. C. C., University of, W., Van Andel Research, I., Vanderbilt, U., Washington, U., Genome Sequencing Center: Broad, I., Washington University in St, L., Genome Characterization Centers, B. C. C. A., Broad, I., Harvard Medical, S., Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, U., University of North, C., University of Southern California Epigenome, C., University of Texas, M. D. A. C. C., Van Andel Research, I., Genome Data Analysis Centers: Broad, I., Brown, U., Harvard Medical, S., Institute for Systems, B., Memorial Sloan Kettering Cancer, C., University of California Santa, C., University of Texas, M. D. A. C. C., Biospecimen Core Resource: International Genomics, C., Research Institute at Nationwide Children’s, H., Tissue Source Sites: Analytic Biologic, S., Asan Medical, C., Asterand, B., Barretos Cancer, H., BioreclamationIvt, Botkin Municipal, C., Chonnam National University Medical, S., Christiana Care Health, S., Cureline, Duke, U., Emory, U., Erasmus, U., Indiana University School of, M., Institute of Oncology of, M., International Genomics, C., Invidumed, Israelitisches Krankenhaus, H., Keimyung University School of, M., Memorial Sloan Kettering Cancer, C., National Cancer Center, G., Ontario Tumour, B., Peter MacCallum Cancer, C., Pusan National University Medical, S., Ribeirão Preto Medical, S., St. Joseph’s, H., Medical, C., St. Petersburg Academic, U., Tayside Tissue, B., University of, D., University of Kansas Medical, C., University of, M., University of North Carolina at Chapel, H., University of Pittsburgh School of, M., University of Texas, M. D. A. C. C., Disease Working Group: Duke, U., Memorial Sloan Kettering Cancer, C., National Cancer, I., University of Texas, M. D. A. C. C., Yonsei University College of, M., Data Coordination Center, C. I., & Project Team: National Institutes of, H. (2017). Integrated genomic characterization of oesophageal carcinoma. Nature, 541(7636), 169-175. https://doi.org/10.1038/nature20805
Cancer Registry of Norway. (2021). Cancer in Norway 2020: cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway. Hentet fra https://www.kreftregisteret.no/globalassets/cancer-in-norway/2020/cin-2020.pdf
Cats, A., Jansen, E. P. M., van Grieken, N. C. T., Sikorska, K., Lind, P., Nordsmark, M., Meershoek-Klein Kranenbarg, E., Boot, H., Trip, A. K., Swellengrebel, H. A. M., van Laarhoven, H. W. M., Putter, H., van Sandick, J. W., van Berge Henegouwen, M. I., Hartgrink, H. H., van Tinteren, H., van de Velde, C. J. H., & Verheij, M. (2018). Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. The Lancet. Oncology, 19(5), 616-628. https://doi.org/10.1016/s1470-2045(18)30132-3
Cense, H. A., van Eijck, C. H., & Tilanus, H. W. (2006). New insights in the lymphatic spread of oesophageal cancer and its implications for the extent of surgical resection. Best Pract Res Clin Gastroenterol., 20(5), 893-906. https://doi.org/10.1016/j.bpg.2006.03.010
Chandrasoma, P., Wickramasinghe, K., Ma, Y., & DeMeester, T. (2007). Is intestinal metaplasia a necessary precursor lesion for adenocarcinomas of the distal esophagus, gastroesophageal junction and gastric cardia? Dis.Esophagus., 20(1), 36-41.
Cheung, H. C., Siu, K. F., & Wong, J. (1987). Is pyloroplasty necessary in esophageal replacement by stomach? A prospective, randomized controlled trial. Surgery, 102(1), 19-24.
Choi, J., Kim, S. G., Kim, J. S., Jung, H. C., & Song, I. S. (2010). Comparison of endoscopic ultrasonography (EUS), positron emission tomography (PET), and computed tomography (CT) in the preoperative locoregional staging of resectable esophageal cancer. Surgical endoscopy, 24(6), 1380-1386. https://doi.org/10.1007/s00464-009-0783-x
Chung, H. C., Bang, Y. J., C, S. F., Qin, S. K., Satoh, T., Shitara, K., Tabernero, J., Van Cutsem, E., Alsina, M., Cao, Z. A., Lu, J., Bhagia, P., Shih, C. S., & Janjigian, Y. Y. (2021). First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. Future Oncol, 17(5), 491-501. https://doi.org/10.2217/fon-2020-0737
Conroy, T., Galais, M.-P., Raoul, J.-L., Bouché, O., Gourgou-Bourgade, S., Douillard, J.-Y., Etienne, P.-L., Boige, V., Martel-Lafay, I., Michel, P., Llacer-Moscardo, C., François, E., Créhange, G., Abdelghani, M. B., Juzyna, B., Bedenne, L., Adenis, A., Fédération Francophone de Cancérologie, D., & Group, U.-G. (2014). Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. The Lancet. Oncology, 15(3), 305-314. https://doi.org/10.1016/S1470-2045(14)70028-2
Conroy, T., Yataghene, Y., Etienne, P. L., Michel, P., Senellart, H., Raoul, J. L., Mineur, L., Rives, M., Mirabel, X., Lamezec, B., Rio, E., Le, P. E., Peiffert, D., & Adenis, A. (2010). Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer. Br J Cancer, 103(9), 1349-1355.
Cook, M. B., Kamangar, F., Whiteman, D. C., Freedman, N. D., Gammon, M. D., Bernstein, L., Brown, L. M., Risch, H. A., Ye, W., Sharp, L., Pandeya, N., Webb, P. M., Wu, A. H., Ward, M. H., Giffen, C., Casson, A. G., Abnet, C. C., Murray, L. J., Corley, D. A., Nyren, O., Vaughan, T. L., & Chow, W. H. (2010). Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. Journal of the National Cancer Institute, 102(17), 1344-1353. https://doi.org/10.1093/jnci/djq289
Cooper, J. S., Guo, M. D., Herskovic, A., Macdonald, J. S., Martenson, J. A., Jr., al-Sarraf, M., Byhardt, R., Russell, A. H., Beitler, J. J., Spencer, S., Asbell, S. O., Graham, M. V., & Leichman, L. L. (1999). Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA, 281(17), 1623-1627.
Cunningham, D., Allum, W. H., Stenning, S. P., Thompson, J. N., Van de Velde, C. J., Nicolson, M., Scarffe, J. H., Lofts, F. J., Falk, S. J., Iveson, T. J., Smith, D. B., Langley, R. E., Verma, M., Weeden, S., Chua, Y. J., & Participants, M. T. (2006). Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 355(1), 11-20. https://doi.org/10.1056/NEJMoa055531
Cunningham, D., Starling, N., Rao, S., Iveson, T., Nicolson, M., Coxon, F., Middleton, G., Daniel, F., Oates, J., & Norman, A. R. (2008). Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med, 358(1), 36-46.
D'Journo, X. B., & Thomas, P. A. (2014). Current management of esophageal cancer. Journal of thoracic disease, 6 Suppl 2, S253-264. https://doi.org/10.3978/j.issn.2072-1439.2014.04.16
Davies, A. R., Deans, D. A., Penman, I., Plevris, J. N., Fletcher, J., Wall, L., Phillips, H., Gilmour, H., Patel, D., de, B. A., & Paterson-Brown, S. (2006). The multidisciplinary team meeting improves staging accuracy and treatment selection for gastro-esophageal cancer. Dis.Esophagus., 19(6), 496-503.
de Jonge, P. J., van Blankenstein, M., Grady, W. M., & Kuipers, E. J. (2014). Barrett's oesophagus: epidemiology, cancer risk and implications for management. Gut, 63(1), 191-202. https://doi.org/10.1136/gutjnl-2013-305490
Dehdashti, F., & Siegel, B. A. (2006). PET and PET/CT Imaging in Esophageal and Gastric Cancers. I: P. E. Valk, D. Delbeke, D. L. Bailey, D. W. Townsend, & M. N. Maisey (red.), Positron Emission Tomography: Clinical Practice (s. 165-180). London: Springer London. (Reprinted from).
Den norske patologforening. (2018). Veileder i biopsibesvarelse av maligne svulster (3. utgave (versjon 5.0 – 2018) utg.). [s.l.]: Den norske patologforening. Hentet fra https://www.legeforeningen.no/contentassets/961983a735a24fc5815dff5b3fa1ce01/veileder-i-besvarelse-av-maligne-svulster-2018-versjon-5.pdf
di Pietro, M., Fitzgerald, R. C., & BSG Barrett's guidelines working group. (2018). Revised British Society of Gastroenterology recommendation on the diagnosis and management of Barrett's oesophagus with low-grade dysplasia. Gut, 67(2), 392-393. https://doi.org/10.1136/gutjnl-2017-314135
Dolan, J. P., Kaur, T., Diggs, B. S., Luna, R. A., Sheppard, B. C., Schipper, P. H., Tieu, B. H., Bakis, G., Vaccaro, G. M., Holland, J. M., Gatter, K. M., Conroy, M. A., Thomas, C. A., Jr., & Hunter, J. G. (2016). Significant understaging is seen in clinically staged T2N0 esophageal cancer patients undergoing esophagectomy. Dis.Esophagus., 29(4), 320-325. https://doi.org/10.1111/dote.12334
Enzinger, P. C., Burtness, B. A., Niedzwiecki, D., Ye, X., Douglas, K., Ilson, D. H., Villaflor, V. M., Cohen, S. J., Mayer, R. J., Venook, A., Benson, A. B., 3rd, & Goldberg, R. M. (2016). CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34(23), 2736-2742. https://doi.org/10.1200/JCO.2015.65.5092
Faglige anbefalinger for strålebehandling ved øsofaguscancer. (2009). Østerås: Statens strålevern. https://dsa.no/publikasjoner/stralevernrapport-7-2017-faglige-anbefalinger-for-kurativ-stralebehandling-ved-smacellet-lungecanser/StralevernRapport_7-2017_Faglige%20anbefalinger%20for%20SCLC.pdf
Far, A. E., Aghakhani, A., Hamkar, R., Ramezani, A., Pishbigar, H. F., Mirmomen, S., Roshan, M. R., Vahidi, S., Shahnazi, V., & Deljoodokht, Z. (2007). Frequency of human papillomavirus infection in oesophageal squamous cell carcinoma in Iranian patients. Scandinavian journal of infectious diseases, 39(1), 58-62. https://doi.org/10.1080/00365540600740496
Ferlay, J., Ervik, M., Lam, F., Colombet, M., Mery, L., Piñeros, M., Znaor, A., Soerjomataram, I., & Bray, F. Global Cancer Observatory: Cancer Today.Lyon: International Agency for Research on Cancer. fra https://gco.iarc.fr/today
Fitzgerald, R. C., di Pietro, M., Ragunath, K., Ang, Y., Kang, J. Y., Watson, P., Trudgill, N., Patel, P., Kaye, P. V., Sanders, S., O'Donovan, M., Bird-Lieberman, E., Bhandari, P., Jankowski, J. A., Attwood, S., Parsons, S. L., Loft, D., Lagergren, J., Moayyedi, P., Lyratzopoulos, G., & de Caestecker, J. (2014). British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut, 63(1), 7-42. https://doi.org/10.1136/gutjnl-2013-305372
Ford, H. E., Marshall, A., Bridgewater, J. A., Janowitz, T., Coxon, F. Y., Wadsley, J., Mansoor, W., Fyfe, D., Madhusudan, S., Middleton, G. W., Swinson, D., Falk, S., Chau, I., Cunningham, D., Kareclas, P., Cook, N., Blazeby, J. M., & Dunn, J. A. (2014). Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. The Lancet. Oncology, 15(1), 78-86. https://doi.org/10.1016/s1470-2045(13)70549-7
Fuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. V., Aprile, G., Ferry, D. R., Melichar, B., Tehfe, M., Topuzov, E., Zalcberg, J. R., Chau, I., Campbell, W., Sivanandan, C., Pikiel, J., Koshiji, M., Hsu, Y., Liepa, A. M., Gao, L., Schwartz, J. D., & Tabernero, J. (2014). Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet, 383(9911), 31-39. https://doi.org/10.1016/s0140-6736(13)61719-5
Fumagali, U. (1996). Resective surgery for cancer of the thoracic esophagus. Results of a Consensus Conference held at the VIth World Congress of the International Society for Diseases of the Esophagus. Diseases of the Esophagus, 9 (Suppl. 1), 30-38.
Gkika, E., Gauler, T., Eberhardt, W., Stahl, M., Stuschke, M., & Pottgen, C. (2014). Long-term results of definitive radiochemotherapy in locally advanced cancers of the cervical esophagus. Dis.Esophagus., 27(7), 678-684. https://doi.org/10.1111/dote.12146
Guidelines for the diagnosis and management of Barrett's columnar-lined oesophagus. (2005). London: British Society of Gastroenterology. Hentet fra
https://www.bsg.org.uk/clinical-resource/bsg-guidelines-on-the-diagnosis-and-management-of-barretts-oesophagus/
Guimbaud, R., Louvet, C., Ries, P., Ychou, M., Maillard, E., Andre, T., Gornet, J. M., Aparicio, T., Nguyen, S., Azzedine, A., Etienne, P. L., Boucher, E., Rebischung, C., Hammel, P., Rougier, P., Bedenne, L., & Bouche, O. (2014). Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(31), 3520-3526. https://doi.org/10.1200/jco.2013.54.1011
Hagens, E. R. C., van Berge Henegouwen, M. I., Cuesta, M. A., & Gisbertz, S. S. (2017). The extent of lymphadenectomy in esophageal resection for cancer should be standardized. Journal of thoracic disease, 9(Suppl 8), S713-s723. https://doi.org/10.21037/jtd.2017.07.42
Hagens, E. R. C., van Berge Henegouwen, M. I., & Gisbertz, S. S. (2020). Distribution of Lymph Node Metastases in Esophageal Carcinoma Patients Undergoing Upfront Surgery: A Systematic Review. Cancers (Basel), 12(6). https://doi.org/10.3390/cancers12061592
Hagens, E. R. C., van Berge Henegouwen, M. I., van Sandick, J. W., Cuesta, M. A., van der Peet, D. L., Heisterkamp, J., Nieuwenhuijzen, G. A. P., Rosman, C., Scheepers, J. J. G., Sosef, M. N., van Hillegersberg, R., Lagarde, S. M., Nilsson, M., Räsänen, J., Nafteux, P., Pattyn, P., Hölscher, A. H., Schröder, W., Schneider, P. M., Mariette, C., Castoro, C., Bonavina, L., Rosati, R., de Manzoni, G., Mattioli, S., Garcia, J. R., Pera, M., Griffin, M., Wilkerson, P., Chaudry, M. A., Sgromo, B., Tucker, O., Cheong, E., Moorthy, K., Walsh, T. N., Reynolds, J., Tachimori, Y., Inoue, H., Matsubara, H., Kosugi, S. I., Chen, H., Law, S. Y. K., Pramesh, C. S., Puntambekar, S. P., Murthy, S., Linden, P., Hofstetter, W. L., Kuppusamy, M. K., Shen, K. R., Darling, G. E., Sabino, F. D., Grimminger, P. P., Meijer, S. L., Bergman, J., Hulshof, M., van Laarhoven, H. W. M., Mearadji, B., Bennink, R. J., Annema, J. T., Dijkgraaf, M. G. W., & Gisbertz, S. S. (2019). Distribution of lymph node metastases in esophageal carcinoma [TIGER study]: study protocol of a multinational observational study. BMC Cancer, 19(1), 662. https://doi.org/10.1186/s12885-019-5761-7
Haisley, K. R., Abdelmoaty, W. F., & Dunst, C. M. (2021). Laparoscopic Transhiatal Esophagectomy for Invasive Esophageal Adenocarcinoma. J Gastrointest Surg, 25(1), 9-15. https://doi.org/10.1007/s11605-019-04506-4
Halm, E. A., Lee, C., & Chassin, M. R. (2002). Is volume related to outcome in health care? A systematic review and methodologic critique of the literature. Ann Intern Med., 137(6), 511-520.
Harada, K., Hwang, H., Wang, X., Abdelhakeem, A., Iwatsuki, M., Blum Murphy, M. A., Maru, D. M., Weston, B., Lee, J. H., Rogers, J. E., Thomas, I., Shanbhag, N., Zhao, M., Bhutani, M. S., Nguyen, Q. N., Swisher, S. G., Ikoma, N., Badgwell, B. D., Hofstetter, W. L., & Ajani, J. A. (2021). Frequency and Implications of Paratracheal Lymph Node Metastases in Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. Ann Surg., 273(4), 751-757. https://doi.org/10.1097/sla.0000000000003383
Hauge, T., Amdal, C. D., Falk, R. S., Johannessen, H.-O., & Johnson, E. (2020). Long-term outcome in patients operated with hybrid esophagectomy for esophageal cancer – a cohort study. Acta Oncologica, 59(7), 859-865. https://doi.org/10.1080/0284186X.2020.1750694
Haverkamp, L., Seesing, M. F., Ruurda, J. P., Boone, J., & R, V. H. (2017). Worldwide trends in surgical techniques in the treatment of esophageal and gastroesophageal junction cancer. Dis.Esophagus., 30(1), 1-7. https://doi.org/10.1111/dote.12480
Helse og omsorgstjenester: kreft. (5 mars 2012). [nettdokument]. Oslo: Helsedirektoratet. Hentet Mai 2012.
Hironaka, S., Ueda, S., Yasui, H., Nishina, T., Tsuda, M., Tsumura, T., Sugimoto, N., Shimodaira, H., Tokunaga, S., Moriwaki, T., Esaki, T., Nagase, M., Fujitani, K., Yamaguchi, K., Ura, T., Hamamoto, Y., Morita, S., Okamoto, I., Boku, N., & Hyodo, I. (2013). Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(35), 4438-4444. https://doi.org/10.1200/JCO.2012.48.5805
Hoeppner, J., Lordick, F., Brunner, T., Glatz, T., Bronsert, P., Rothling, N., Schmoor, C., Lorenz, D., Ell, C., Hopt, U. T., & Siewert, J. R. (2016). ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). BMC Cancer, 16, 503. https://doi.org/10.1186/s12885-016-2564-y
Hofmann, M., Stoss, O., Shi, D., Buttner, R., van de Vijver, M., Kim, W., Ochiai, A., Ruschoff, J., & Henkel, T. (2008). Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology, 52(7), 797-805. https://doi.org/10.1111/j.1365-2559.2008.03028.x
Homs, M. Y., Steyerberg, E. W., Eijkenboom, W. M., Tilanus, H. W., Stalpers, L. J., Bartelsman, J. F., van Lanschot, J. J., Wijrdeman, H. K., Mulder, C. J., Reinders, J. G., Boot, H., Aleman, B. M., Kuipers, E. J., & Siersema, P. D. (2005). Palliatieve behandeling voor slokdarmkanker met passageklachten: gunstiger uitkomsten van eenmalige inwendige brachytherapie dan van plaatsing van een zelfexpanderende stent; multicentrisch, gerandomiseerd onderzoek [Palliative treatment of esophageal cancer with dysphagia: more favourable outcome from single-dose internal brachytherapy than from the placement of a self-expanding stent; a multicenter randomised study]. Ned Tijdschr Geneeskd., 149(50), 2800-2806 [På nederlandsk].
Homs, M. Y. V., Steyerberg, E. W., Eijkenboom, W. M. H., Tilanus, H. W., Stalpers, L. J. A., Bartelsman, J. F. W. M., van Lanschot, J. J. B., Wijrdeman, H. K., Mulder, C. J. J., Reinders, J. G., Boot, H., Aleman, B. M. P., Kuipers, E. J., & Siersema, P. D. (2004). Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet, 364(9444), 1497-1504. https://doi.org/10.1016/S0140-6736(04)17272-3
Horgan, S., Berger, R. A., Elli, E. F., & Espat, N. J. (2003). Robotic-assisted minimally invasive transhiatal esophagectomy. The American surgeon, 69(7), 624-626.
Hosch, S. B., Stoecklein, N. H., Pichlmeier, U., Rehders, A., Scheunemann, P., Niendorf, A., Knoefel, W. T., & Izbicki, J. R. (2001). Esophageal cancer: the mode of lymphatic tumor cell spread and its prognostic significance. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19(7), 1970-1975. https://doi.org/10.1200/jco.2001.19.7.1970
Huang, S. H., Lockwood, G., Brierley, J., Cummings, B., Kim, J., Wong, R., Bayley, A., & Ringash, J. (2008). Effect of concurrent high-dose cisplatin chemotherapy and conformal radiotherapy on cervical esophageal cancer survival. International journal of radiation oncology, biology, physics, 71(3), 735-740. https://doi.org/10.1016/j.ijrobp.2007.10.022
Huang, Y., Wang, H., Luo, G., Zhang, Y., Wang, L., & Li, K. (2017). A systematic review and network meta-analysis of neoadjuvant therapy combined with surgery for patients with resectable esophageal squamous cell carcinoma. International journal of surgery (London, England), 38, 41-47. https://doi.org/10.1016/j.ijsu.2016.12.035
Hulscher, J. B., & van Lanschot, J. J. (2005). Individualised surgical treatment of patients with an adenocarcinoma of the distal oesophagus or gastro-oesophageal junction. Dig Surg., 22(3), 130-134.
Hulscher, J. B., van Sandick, J. W., de Boer, A. G., Wijnhoven, B. P., Tijssen, J. G., Fockens, P., Stalmeier, P. F., Ten Kate, F. J., van, D. H., Obertop, H., Tilanus, H. W., & van Lanschot, J. J. (2002). Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med, 347(21), 1662-1669.
Hulshof, M., Geijsen, E. D., Rozema, T., Oppedijk, V., Buijsen, J., Neelis, K. J., Nuyttens, J., van der Sangen, M. J. C., Jeene, P. M., Reinders, J. G., van Berge Henegouwen, M. I., Thano, A., van Hooft, J. E., van Laarhoven, H. W. M., & van der Gaast, A. (2021). Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(25), 2816-2824. https://doi.org/10.1200/jco.20.03697
International Agency for Research on Cancer. (2019). Digestive system tumours (5th ed. utg. Vol. Vol. 1). Lyon: International Agency for Research on Cancer.
Islami, F., Boffetta, P., Ren, J. S., Pedoeim, L., Khatib, D., & Kamangar, F. (2009). High-temperature beverages and foods and esophageal cancer risk--a systematic review. Int J Cancer, 125(3), 491-524. https://doi.org/10.1002/ijc.24445
Islami, F., Fedirko, V., Tramacere, I., Bagnardi, V., Jenab, M., Scotti, L., Rota, M., Corrao, G., Garavello, W., Schuz, J., Straif, K., Negri, E., Boffetta, P., & La Vecchia, C. (2011). Alcohol drinking and esophageal squamous cell carcinoma with focus on light-drinkers and never-smokers: a systematic review and meta-analysis. Int J Cancer, 129(10), 2473-2484. https://doi.org/10.1002/ijc.25885
Islami, F., & Kamangar, F. (2008). Helicobacter pylori and esophageal cancer risk: a meta-analysis. Cancer Prev Res, 1(5), 329-338.
Jamieson, G. G., Lamb, P. J., & Thompson, S. K. (2009). The role of lymphadenectomy in esophageal cancer. Ann Surg., 250(2), 206-209.
Janjigian, Y. Y., Kawazoe, A., Yanez, P. E., Luo, S., Lonardi, S., Kolesnik, O., Barajas, O., Bai, Y., Shen, L., Tang, Y., Wyrwicz, L., Shitara, K., Qin, S., Cutsem, E. V., Tabernero, J., Li, L., Shih, C.-S., Bhagia, P., Chung, H. C. C., & investigators, o. b. o. t. K.-. (2021). Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study. Journal of Clinical Oncology, 39(15_suppl), 4013-4013. https://doi.org/10.1200/JCO.2021.39.15_suppl.4013
Janjigian, Y. Y., Shitara, K., Moehler, M., Garrido, M., Salman, P., Shen, L., Wyrwicz, L., Yamaguchi, K., Skoczylas, T., Campos Bragagnoli, A., Liu, T., Schenker, M., Yanez, P., Tehfe, M., Kowalyszyn, R., Karamouzis, M. V., Bruges, R., Zander, T., Pazo-Cid, R., Hitre, E., Feeney, K., Cleary, J. M., Poulart, V., Cullen, D., Lei, M., Xiao, H., Kondo, K., Li, M., & Ajani, J. A. (2021). First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet, 398(10294), 27-40. https://doi.org/10.1016/s0140-6736(21)00797-2
Japanese Classification of Esophageal Cancer, 11th Edition: part I. (2017). Esophagus, 14(1), 1-36. https://doi.org/10.1007/s10388-016-0551-7
Jezerskyte, E., Mertens, A. C., van Dieren, S., Eshuis, W. J., Sprangers, M. A. G., van Berge Henegouwen, M. I., & Gisbertz, S. S. (2020). Gastrectomy Versus Esophagectomy For Gastroesophageal Junction Tumors: Short- And Long-term Outcomes From the Dutch Upper GI Cancer Audit. Ann Surg. https://doi.org/10.1097/sla.0000000000004610
Kamarajah, S. K., Phillips, A. W., Griffiths, E. A., Ferri, L., Hofstetter, W. L., & Markar, S. R. (2021). Esophagectomy or Total Gastrectomy for Siewert 2 Gastroesophageal Junction (GEJ) Adenocarcinoma? A Registry-Based Analysis. Ann Surg Oncol, 28(13), 8485-8494. https://doi.org/10.1245/s10434-021-10346-x
Kang, Y. K., Boku, N., Satoh, T., Ryu, M. H., Chao, Y., Kato, K., Chung, H. C., Chen, J. S., Muro, K., Kang, W. K., Yeh, K. H., Yoshikawa, T., Oh, S. C., Bai, L. Y., Tamura, T., Lee, K. W., Hamamoto, Y., Kim, J. G., Chin, K., Oh, D. Y., Minashi, K., Cho, J. Y., Tsuda, M., & Chen, L. T. (2017). Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 390(10111), 2461-2471. https://doi.org/10.1016/s0140-6736(17)31827-5
Kastelein, F., Spaander, M. C., Biermann, K., Steyerberg, E. W., Kuipers, E. J., & Bruno, M. J. (2011). Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus. Gastroenterology, 141(6), 2000-2008; quiz e2013-2004. https://doi.org/10.1053/j.gastro.2011.08.036
Kato, K., Cho, B. C., Takahashi, M., Okada, M., Lin, C. Y., Chin, K., Kadowaki, S., Ahn, M. J., Hamamoto, Y., Doki, Y., Yen, C. C., Kubota, Y., Kim, S. B., Hsu, C. H., Holtved, E., Xynos, I., Kodani, M., & Kitagawa, Y. (2019). Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. The Lancet. Oncology, 20(11), 1506-1517. https://doi.org/10.1016/s1470-2045(19)30626-6
Kelly, R. J., Ajani, J. A., Kuzdzal, J., Zander, T., Van Cutsem, E., Piessen, G., Mendez, G., Feliciano, J., Motoyama, S., Lièvre, A., Uronis, H., Elimova, E., Grootscholten, C., Geboes, K., Zafar, S., Snow, S., Ko, A. H., Feeney, K., Schenker, M., Kocon, P., Zhang, J., Zhu, L., Lei, M., Singh, P., Kondo, K., Cleary, J. M., & Moehler, M. (2021). Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med, 384(13), 1191-1203. https://doi.org/10.1056/NEJMoa2032125
Keszei, A. P., Schouten, L. J., Goldbohm, R. A., & van den Brandt, P. A. (2012). Red and processed meat consumption and the risk of esophageal and gastric cancer subtypes in The Netherlands Cohort Study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 23(9), 2319-2326. https://doi.org/10.1093/annonc/mdr615
Khanna, L. G., & Gress, F. G. (2015). Preoperative evaluation of oesophageal adenocarcinoma. Best Pract Res Clin Gastroenterol., 29(1), 179-191. https://doi.org/10.1016/j.bpg.2014.12.005
Kidane, B., Coughlin, S., Vogt, K., & Malthaner, R. (2015). Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev., 5, CD001556. https://doi.org/10.1002/14651858.CD001556.pub3
Killeen, S. D., O'Sullivan, M. J., Coffey, J. C., Kirwan, W. O., & Redmond, H. P. (2005). Provider volume and outcomes for oncological procedures. Br J Surg., 92(4), 389-402.
Kim, S. T., Cristescu, R., Bass, A. J., Kim, K. M., Odegaard, J. I., Kim, K., Liu, X. Q., Sher, X., Jung, H., Lee, M., Lee, S., Park, S. H., Park, J. O., Park, Y. S., Lim, H. Y., Lee, H., Choi, M., Talasaz, A., Kang, P. S., Cheng, J., Loboda, A., Lee, J., & Kang, W. K. (2018). Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med, 24(9), 1449-1458. https://doi.org/10.1038/s41591-018-0101-z
Klevebro, F., Alexandersson von Dobeln, G., Wang, N., Johnsen, G., Jacobsen, A. B., Friesland, S., Hatlevoll, I., Glenjen, N. I., Lind, P., Tsai, J. A., Lundell, L., & Nilsson, M. (2016). A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 27(4), 660-667. https://doi.org/10.1093/annonc/mdw010
Kojima, T., Shah, M. A., Muro, K., Francois, E., Adenis, A., Hsu, C. H., Doi, T., Moriwaki, T., Kim, S. B., Lee, S. H., Bennouna, J., Kato, K., Shen, L., Enzinger, P., Qin, S. K., Ferreira, P., Chen, J., Girotto, G., de la Fouchardiere, C., Senellart, H., Al-Rajabi, R., Lordick, F., Wang, R., Suryawanshi, S., Bhagia, P., Kang, S. P., & Metges, J. P. (2020). Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 38(35), 4138-4148. https://doi.org/10.1200/jco.20.01888
Komeda, Y., Bruno, M., & Koch, A. (2014). EMR is not inferior to ESD for early Barrett's and EGJ neoplasia: An extensive review on outcome, recurrence and complication rates. Endoscopy international open, 2(2), E58-64. https://doi.org/10.1055/s-0034-1365528
Koyanagi, K., Kato, F., Kanamori, J., Daiko, H., Ozawa, S., & Tachimori, Y. (2018). Clinical significance of esophageal invasion length for the prediction of mediastinal lymph node metastasis in Siewert type II adenocarcinoma: A retrospective single-institution study. Ann Gastroenterol Surg, 2(3), 187-196. https://doi.org/10.1002/ags3.12069
Kranzfelder, M., Schuster, T., Geinitz, H., Friess, H., & Buchler, P. (2011). Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer. Br J Surg., 98(6), 768-783. https://doi.org/10.1002/bjs.7455
Kurokawa, Y., Hiki, N., Yoshikawa, T., Kishi, K., Ito, Y., Ohi, M., Wada, N., Takiguchi, S., Mine, S., Hasegawa, S., Matsuda, T., & Takeuchi, H. (2015). Mediastinal lymph node metastasis and recurrence in adenocarcinoma of the esophagogastric junction. Surgery, 157(3), 551-555. https://doi.org/10.1016/j.surg.2014.08.099
Lagergren, J., Bergstrom, R., Adami, H. O., & Nyren, O. (2000). Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med., 133(3), 165-175.
Lagergren, J., Bergstrom, R., Lindgren, A., & Nyren, O. (1999). Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med, 340(11), 825-831.
Lagergren, J., Bergstrom, R., Lindgren, A., & Nyren, O. (2000). The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. Int J Cancer, 85(3), 340-346.
Lagergren, J., Bergstrom, R., & Nyren, O. (1999). Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med., 130(11), 883-890.
Lagergren, J., Ye, W., Lagergren, P., & Lu, Y. (2010). The risk of esophageal adenocarcinoma after antireflux surgery. Gastroenterology, 138(4), 1297-1301. https://doi.org/10.1053/j.gastro.2010.01.004
Lai, A., Lipka, S., Kumar, A., Sethi, S., Bromberg, D., Li, N., Shen, H., Stefaniwsky, L., & Brady, P. (2018). Role of Esophageal Metal Stents Placement and Combination Therapy in Inoperable Esophageal Carcinoma: A Systematic Review and Meta-analysis. Digestive diseases and sciences, 63(4), 1025-1034. https://doi.org/10.1007/s10620-018-4957-z
Lee, Y. C., Marron, M., Benhamou, S., Bouchardy, C., Ahrens, W., Pohlabeln, H., Lagiou, P., Trichopoulos, D., Agudo, A., Castellsague, X., Bencko, V., Holcatova, I., Kjaerheim, K., Merletti, F., Richiardi, L., Macfarlane, G. J., Macfarlane, T. V., Talamini, R., Barzan, L., Canova, C., Simonato, L., Conway, D. I., McKinney, P. A., Lowry, R. J., Sneddon, L., Znaor, A., Healy, C. M., McCartan, B. E., Brennan, P., & Hashibe, M. (2009). Active and involuntary tobacco smoking and upper aerodigestive tract cancer risks in a multicenter case-control study. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 18(12), 3353-3361. https://doi.org/10.1158/1055-9965.epi-09-0910
Leers, J. M., Knepper, L., van der Veen, A., Schröder, W., Fuchs, H., Schiller, P., Hellmich, M., Zettelmeyer, U., Brosens, L. A. A., Quaas, A., Ruurda, J. P., van Hillegersberg, R., & Bruns, C. J. (2020). The CARDIA-trial protocol: a multinational, prospective, randomized, clinical trial comparing transthoracic esophagectomy with transhiatal extended gastrectomy in adenocarcinoma of the gastroesophageal junction (GEJ) type II. BMC Cancer, 20(1), 781. https://doi.org/10.1186/s12885-020-07152-1
Leong, T., Smithers, B. M., Michael, M., Gebski, V., Boussioutas, A., Miller, D., Simes, J., Zalcberg, J., Haustermans, K., Lordick, F., Schuhmacher, C., Swallow, C., Darling, G., & Wong, R. (2015). TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG). BMC Cancer, 15, 532. https://doi.org/10.1186/s12885-015-1529-x
Levard, H., Pouliquen, X., Hay, J. M., Fingerhut, A., Langlois-Zantain, O., Huguier, M., Lozach, P., & Testart, J. (1998). 5-Fluorouracil and cisplatin as palliative treatment of advanced oesophageal squamous cell carcinoma. A multicentre randomised controlled trial. The French Associations for Surgical Research. Eur J Surg., 164(11), 849-857. https://doi.org/10.1080/110241598750005273
Li, X., Gao, C., Yang, Y., Zhou, F., Li, M., Jin, Q., & Gao, L. (2014). Systematic review with meta-analysis: the association between human papillomavirus infection and oesophageal cancer. Alimentary pharmacology & therapeutics, 39(3), 270-281. https://doi.org/10.1111/apt.12574
Liu, J., Wang, J., Leng, Y., & Lv, C. (2013). Intake of fruit and vegetables and risk of esophageal squamous cell carcinoma: a meta-analysis of observational studies. Int J Cancer, 133(2), 473-485. https://doi.org/10.1002/ijc.28024
Lu, Z., Fang, Y., Liu, C., Zhang, X., Xin, X., He, Y., Cao, Y., Jiao, X., Sun, T., Pang, Y., Wang, Y., Zhou, J., Qi, C., Gong, J., Wang, X., Li, J., Tang, L., & Shen, L. (2021). Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(7), 748-756. https://doi.org/10.1200/jco.20.01254
Löfdahl, H. E., Lu, Y., Lagergren, P., & Lagergren, J. (2013). Risk factors for esophageal adenocarcinoma after antireflux surgery. Ann Surg., 257(4), 579-582. https://doi.org/10.1097/SLA.0b013e3182888384
Malik, S., Sharma, G., Sanaka, M. R., & Thota, P. N. (2018). Role of endoscopic therapy in early esophageal cancer. World journal of gastroenterology, 24(35), 3965-3973. https://doi.org/10.3748/wjg.v24.i35.3965
Malthaner, R. A., Collin, S., & Fenlon, D. (2006). Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev., (3), CD001556.
Mannath, J., Subramanian, V., Hawkey, C. J., & Ragunath, K. (2010). Narrow band imaging for characterization of high grade dysplasia and specialized intestinal metaplasia in Barrett's esophagus: a meta-analysis. Endoscopy, 42(5), 351-359.
Maret-Ouda, J., Konings, P., Lagergren, J., & Brusselaers, N. (2016). Antireflux Surgery and Risk of Esophageal Adenocarcinoma: A Systematic Review and Meta-analysis. Ann Surg., 263(2), 251-257. https://doi.org/10.1097/sla.0000000000001438
Mariette, C., Dahan, L., Mornex, F., Maillard, E., Thomas, P. A., Meunier, B., Boige, V., Pezet, D., Robb, W. B., Le Brun-Ly, V., Bosset, J. F., Mabrut, J. Y., Triboulet, J. P., Bedenne, L., & Seitz, J. F. (2014). Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(23), 2416-2422. https://doi.org/10.1200/jco.2013.53.6532
Mariette, C., Markar, S. R., Dabakuyo-Yonli, T. S., Meunier, B., Pezet, D., Collet, D., D'Journo, X. B., Brigand, C., Perniceni, T., Carrère, N., Mabrut, J. Y., Msika, S., Peschaud, F., Prudhomme, M., Bonnetain, F., & Piessen, G. (2019). Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer. N Engl J Med, 380(2), 152-162. https://doi.org/10.1056/NEJMoa1805101
Mariette, C., Meunier, B., Pezet, D., Dalban, C., Collet, D., Thomas, P.-A., Brigand, C., Perniceni, T., Carrere, N., Bonnetain, F., & Piessen, G. (2015). Hybrid minimally invasive versus open oesophagectomy for patients with oesophageal cancer: A multicenter, open-label, randomized phase III controlled trial, the MIRO trial. J Clin Oncol., 33(3_suppl), 5. https://doi.org/10.1200/jco.2015.33.3_suppl.5
Markar, S. R., Gronnier, C., Pasquer, A., Duhamel, A., Beal, H., Théreaux, J., Gagnière, J., Lebreton, G., Brigand, C., Meunier, B., Collet, D., Mariette, C., & AFC, F. w. g. F. (2016). Role of neoadjuvant treatment in clinical T2N0M0 oesophageal cancer: results from a retrospective multi-center European study. European journal of cancer (Oxford, England : 1990), 56, 59-68. https://doi.org/10.1016/j.ejca.2015.11.024
Markar, S. R., Mikhail, S., Malietzis, G., Athanasiou, T., Mariette, C., Sasako, M., & Hanna, G. B. (2016). Influence of Surgical Resection of Hepatic Metastases From Gastric Adenocarcinoma on Long-term Survival: Systematic Review and Pooled Analysis. Ann Surg., 263(6), 1092-1101. https://doi.org/10.1097/sla.0000000000001542
Matsuda, S., Takeuchi, H., Kawakubo, H., & Kitagawa, Y. (2017). Three-field lymph node dissection in esophageal cancer surgery. Journal of thoracic disease, 9(Suppl 8), S731-S740. https://doi.org/10.21037/jtd.2017.03.171
Michalinos, A., Antoniou, S. A., Ntourakis, D., Schizas, D., Ekmektzoglou, K., Angouridis, A., & Johnson, E. O. (2020). Gastric ischemic preconditioning may reduce the incidence and severity of anastomotic leakage after οesophagectomy: a systematic review and meta-analysis. Dis.Esophagus., 33(10). https://doi.org/10.1093/dote/doaa010
Mine, S., Sano, T., Hiki, N., Yamada, K., Kosuga, T., Nunobe, S., & Yamaguchi, T. (2013). Proximal margin length with transhiatal gastrectomy for Siewert type II and III adenocarcinomas of the oesophagogastric junction. Br J Surg., 100(8), 1050-1054. https://doi.org/10.1002/bjs.9170
Mine, S., Watanabe, M., Kumagai, K., Okamura, A., Yuda, M., Hayami, M., Yamashita, K., Imamura, Y., & Ishizuka, N. (2019). Comparison of mediastinal lymph node metastases from adenocarcinoma of the esophagogastric junction versus lower esophageal squamous cell carcinoma with involvement of the esophagogastric junction. Dis.Esophagus., 32(11). https://doi.org/10.1093/dote/doz002
Minsky, B. D., Pajak, T. F., Ginsberg, R. J., Pisansky, T. M., Martenson, J., Komaki, R., Okawara, G., Rosenthal, S. A., & Kelsen, D. P. (2002). INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20(5), 1167-1174.
Mota, F. C., Cecconello, I., Takeda, F. R., Tustumi, F., Sallum, R. A. A., & Bernardo, W. M. (2018). Neoadjuvant therapy or upfront surgery? A systematic review and meta-analysis of T2N0 esophageal cancer treatment options. International journal of surgery (London, England), 54(Pt A), 176-181. https://doi.org/10.1016/j.ijsu.2018.04.053
Münch, S., Pigorsch, S. U., Devečka, M., Dapper, H., Weichert, W., Friess, H., Braren, R., Combs, S. E., & Habermehl, D. (2018). Comparison of definite chemoradiation therapy with carboplatin/paclitaxel or cisplatin/5-fluoruracil in patients with squamous cell carcinoma of the esophagus. Radiat Oncol, 13(1), 139. https://doi.org/10.1186/s13014-018-1085-z
Nafteux, P., Depypere, L., Van Veer, H., Coosemans, W., & Lerut, T. (2017). Principles of esophageal cancer surgery, including surgical approaches and optimal node dissection (2- vs. 3-field). Ann Cardiothorac Surg, 6(2), 152-158. https://doi.org/10.21037/acs.2017.03.04
Nasjonal faglig retningslinje for forebygging og behandling av underernæring. (2009). (IS-1580). Oslo: Helsedirektoratet. Hentet fra http://www.helsedirektoratet.no/publikasjoner/nasjonal-faglig-retningslinje-for-forebygging-og-behandling-av-underernering/Sider/default.aspx
Nasjonal helseplan (2007-2010). (2006). (Særtrykk av St.prp. nr. 1 (2006–2007) kapittel 6). Oslo: Helse- og omsorgsdepartemenetet. Hentet fra http://www.regjeringen.no/upload/HOD/Sykehus/Nasjonal_helseplan_Sartrykk.pdf
Nasjonalt kvalitetsregister for kreft i spiserør og magesekk. (2017). Årsrapport 2016 med resultater og forbedringstiltak. Oslo: Kreftregisteret. Hentet fra https://www.kreftregisteret.no/globalassets/publikasjoner-og-rapporter/arsrapporter/publisert-2017/arsrapport-2016_spiseror-og-magesekkreft.pdf
Norway, C. R. o. (2015). Cancer in Norway 2013: cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway. Hentet fra https://www.kreftregisteret.no/globalassets/cancer-in-norway/2013/cin_2013.pdf
Nuytens, F., Dabakuyo-Yonli, T. S., Meunier, B., Gagniere, J., Collet, D., D'Journo, X. B., Brigand, C., Perniceni, T., Carrere, N., Mabrut, J. Y., Msika, S., Peschaud, F., Prudhomme, M., Markar, S. R., Piessen, G., Federation de Recherche en, C., & French Eso-Gastric Tumors Working, G. (2021). Five-Year Survival Outcomes of Hybrid Minimally Invasive Esophagectomy in Esophageal Cancer: Results of the MIRO Randomized Clinical Trial. JAMA Surgery, 156(4), 323-332. https://doi.org/10.1001/jamasurg.2020.7081
Oesophageal and gastric cancers: diagnosis and assessment. (2001). Improving outcomes in upper gastro-intestinal cancers: the manual (s. 37-40). London: Department of Health. (Reprinted from). Hentet fra http://www.wales.nhs.uk/sites3/documents/362/UpperGIGuidance.pdf
Omloo, J. M., Lagarde, S. M., Hulscher, J. B., Reitsma, J. B., Fockens, P., van Dekken, H., Ten Kate, F. J., Obertop, H., Tilanus, H. W., & van Lanschot, J. J. (2007). Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg., 246(6), 992-1000.
Ovrebo, K. K., Lie, S. A., Laerum, O. D., Svanes, K., & Viste, A. (2012). Long-term survival from adenocarcinoma of the esophagus after transthoracic and transhiatal esophagectomy. World journal of surgical oncology, 10, 130. https://doi.org/10.1186/1477-7819-10-130
Owens, R., Cox, C., Gomberg, S., Pan, S., Radhakrishna, G., Parikh, S., Goody, R., Hingorani, M., Prince, S., Bird, T., Dorey, N., Macgregor, U., Al-Chamali, H., Hurt, C., & Mukherjee, S. (2020). Outcome of Weekly Carboplatin-Paclitaxel-based Definitive Chemoradiation in Oesophageal Cancer in Patients Not Considered to be Suitable for Platinum-Fluoropyrimidine-based Treatment: A Multicentre, Retrospective Review. Clin Oncol (R Coll Radiol), 32(2), 121-130. https://doi.org/10.1016/j.clon.2019.09.058
Pandeya, N., Webb, P. M., Sadeghi, S., Green, A. C., & Whiteman, D. C. (2010). Gastro-oesophageal reflux symptoms and the risks of oesophageal cancer: are the effects modified by smoking, NSAIDs or acid suppressants? Gut, 59(1), 31-38. https://doi.org/10.1136/gut.2009.190827
Pasquali, S., Yim, G., Vohra, R. S., Mocellin, S., Nyanhongo, D., Marriott, P., Geh, J. I., & Griffiths, E. A. (2017). Survival After Neoadjuvant and Adjuvant Treatments Compared to Surgery Alone for Resectable Esophageal Carcinoma: A Network Meta-analysis. Ann Surg., 265(3), 481-491. https://doi.org/10.1097/sla.0000000000001905
Peng, J., Cai, J., Niu, Z. X., & Chen, L. Q. (2015). Early enteral nutrition compared with parenteral nutrition for esophageal cancer patients after esophagectomy: a meta-analysis. Dis.Esophagus., Feb 27 [Epub ahead of print]. https://doi.org/10.1111/dote.12337
Petrick, J. L., Wyss, A. B., Butler, A. M., Cummings, C., Sun, X., Poole, C., Smith, J. S., & Olshan, A. F. (2014). Prevalence of human papillomavirus among oesophageal squamous cell carcinoma cases: systematic review and meta-analysis. Br J Cancer, 110(9), 2369-2377. https://doi.org/10.1038/bjc.2014.96
Phoa, K. N., van Vilsteren, F. G., Weusten, B. L., Bisschops, R., Schoon, E. J., Ragunath, K., Fullarton, G., Di Pietro, M., Ravi, N., Visser, M., Offerhaus, G. J., Seldenrijk, C. A., Meijer, S. L., ten Kate, F. J., Tijssen, J. G., & Bergman, J. J. (2014). Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA, 311(12), 1209-1217. https://doi.org/10.1001/jama.2014.2511
Powell, N., Boyde, A., Tristram, A., Hibbitts, S., & Fiander, A. (2009). The potential impact of human papillomavirus vaccination in contemporary cytologically screened populations may be underestimated: an observational retrospective analysis of invasive cervical cancers. Int J Cancer, 125(10), 2425-2427. https://doi.org/10.1002/ijc.24571
Qu, X. M., Biagi, J. J., Hopman, W. M., & Mahmud, A. (2017). Shifting practice in definitive chemoradiation for localized esophageal cancer. Curr Oncol, 24(5), e379-e387. https://doi.org/10.3747/co.24.3677
Ragunath, K., Krasner, N., Raman, V. S., Haqqani, M. T., & Cheung, W. Y. (2003). A randomized, prospective cross-over trial comparing methylene blue-directed biopsy and conventional random biopsy for detecting intestinal metaplasia and dysplasia in Barrett's esophagus. Endoscopy, 35(12), 998-1003.
Reynolds, J. V., Preston, S. R., O'Neill, B., Lowery, M. A., Baeksgaard, L., Crosby, T., Cunningham, M., Cuffe, S., Griffiths, G. O., Roy, R., Falk, S., Hanna, G., Bartlett, F. R., Parker, I., Alvarez-Iglesias, A., Nilsson, M., Piessen, G., Risum, S., Ravi, N., & McDermott, R. S. (2021). Neo-AEGIS (Neoadjuvant trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (Modified MAGIC or FLOT protocol). (NCT01726452). Journal of Clinical Oncology, 39(15_suppl), 4004-4004. https://doi.org/10.1200/JCO.2021.39.15_suppl.4004
Ringe, K. I., Meyer, S., Ringe, B. P., Winkler, M., Wacker, F., & Raatschen, H. J. (2015). Value of oral effervescent powder administration for multidetector CT evaluation of esophageal cancer. European journal of radiology, 84(2), 215-220. https://doi.org/10.1016/j.ejrad.2014.11.008
Rizk, N. P., Ishwaran, H., Rice, T. W., Chen, L. Q., Schipper, P. H., Kesler, K. A., Law, S., Lerut, T. E., Reed, C. E., Salo, J. A., Scott, W. J., Hofstetter, W. L., Watson, T. J., Allen, M. S., Rusch, V. W., & Blackstone, E. H. (2010). Optimum lymphadenectomy for esophageal cancer. Ann Surg., 251(1), 46-50. https://doi.org/10.1097/SLA.0b013e3181b2f6ee
Rokkas, T., Pistiolas, D., Sechopoulos, P., Robotis, I., & Margantinis, G. (2007). Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 5(12), 1413-1417, 1417.e1411-1412. https://doi.org/10.1016/j.cgh.2007.08.010
Ronellenfitsch, U., Schwarzbach, M., Hofheinz, R., Kienle, P., Kieser, M., Slanger, T. E., Burmeister, B., Kelsen, D., Niedzwiecki, D., Schuhmacher, C., Urba, S., van de Velde, C., Walsh, T. N., Ychou, M., & Jensen, K. (2013). Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data. European journal of cancer (Oxford, England : 1990), 49(15), 3149-3158. https://doi.org/10.1016/j.ejca.2013.05.029
Ronellenfitsch, U., Schwarzbach, M., Hofheinz, R., Kienle, P., Kieser, M., Slanger, T. E., & Jensen, K. (2013). Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. Cochrane Database Syst Rev., 5, CD008107. https://doi.org/10.1002/14651858.CD008107.pub2
Ross, P., Nicolson, M., Cunningham, D., Valle, J., Seymour, M., Harper, P., Price, T., Anderson, H., Iveson, T., Hickish, T., Lofts, F., & Norman, A. (2002). Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20(8), 1996-2004. https://doi.org/10.1200/JCO.2002.08.105
Rubenstein, J. H., & Taylor, J. B. (2010). Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux. Alimentary pharmacology & therapeutics, 32(10), 1222-1227. https://doi.org/10.1111/j.1365-2036.2010.04471.x
Samson, P., Puri, V., Robinson, C., Lockhart, C., Carpenter, D., Broderick, S., Kreisel, D., Krupnick, A. S., Patterson, G. A., Meyers, B., & Crabtree, T. (2016). Clinical T2N0 Esophageal Cancer: Identifying Pretreatment Characteristics Associated With Pathologic Upstaging and the Potential Role for Induction Therapy. The Annals of thoracic surgery, 101(6), 2102-2111. https://doi.org/10.1016/j.athoracsur.2016.01.033
Sgourakis, G., Gockel, I., Radtke, A., Dedemadi, G., Goumas, K., Mylona, S., Lang, H., Tsiamis, A., & Karaliotas, C. (2010). The use of self-expanding stents in esophageal and gastroesophageal junction cancer palliation: a meta-analysis and meta-regression analysis of outcomes. Digestive diseases and sciences, 55(11), 3018-3030. https://doi.org/10.1007/s10620-010-1250-1
Shah, M. A., Janjigian, Y. Y., Stoller, R., Shibata, S., Kemeny, M., Krishnamurthi, S., Su, Y. B., Ocean, A., Capanu, M., Mehrotra, B., Ritch, P., Henderson, C., & Kelsen, D. P. (2015). Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33(33), 3874-3879. https://doi.org/10.1200/jco.2015.60.7465
Shapiro, J., van Lanschot, J. J. B., Hulshof, M., van Hagen, P., van Berge Henegouwen, M. I., Wijnhoven, B. P. L., van Laarhoven, H. W. M., Nieuwenhuijzen, G. A. P., Hospers, G. A. P., Bonenkamp, J. J., Cuesta, M. A., Blaisse, R. J. B., Busch, O. R. C., Ten Kate, F. J. W., Creemers, G. M., Punt, C. J. A., Plukker, J. T. M., Verheul, H. M. W., Bilgen, E. J. S., van Dekken, H., van der Sangen, M. J. C., Rozema, T., Biermann, K., Beukema, J. C., Piet, A. H. M., van Rij, C. M., Reinders, J. G., Tilanus, H. W., Steyerberg, E. W., & van der Gaast, A. (2015). Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. The Lancet. Oncology, 16(9), 1090-1098. https://doi.org/10.1016/s1470-2045(15)00040-6
Shiozaki, H., Yano, M., Tsujinaka, T., Inoue, M., Tamura, S., Doki, Y., Yasuda, T., Fujiwara, Y., & Monden, M. (2001). Lymph node metastasis along the recurrent nerve chain is an indication for cervical lymph node dissection in thoracic esophageal cancer. Dis.Esophagus., 14(3-4), 191-196. https://doi.org/10.1046/j.1442-2050.2001.00206.x
Shitara, K., Bang, Y. J., Iwasa, S., Sugimoto, N., Ryu, M. H., Sakai, D., Chung, H. C., Kawakami, H., Yabusaki, H., Lee, J., Saito, K., Kawaguchi, Y., Kamio, T., Kojima, A., Sugihara, M., & Yamaguchi, K. (2020). Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med, 382(25), 2419-2430. https://doi.org/10.1056/NEJMoa2004413
Shitara, K., Doi, T., Dvorkin, M., Mansoor, W., Arkenau, H. T., Prokharau, A., Alsina, M., Ghidini, M., Faustino, C., Gorbunova, V., Zhavrid, E., Nishikawa, K., Hosokawa, A., Yalçın, Ş., Fujitani, K., Beretta, G. D., Cutsem, E. V., Winkler, R. E., Makris, L., Ilson, D. H., & Tabernero, J. (2018). Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology, 19(11), 1437-1448. https://doi.org/10.1016/s1470-2045(18)30739-3
Shitara, K., Van Cutsem, E., Bang, Y. J., Fuchs, C., Wyrwicz, L., Lee, K. W., Kudaba, I., Garrido, M., Chung, H. C., Lee, J., Castro, H. R., Mansoor, W., Braghiroli, M. I., Karaseva, N., Caglevic, C., Villanueva, L., Goekkurt, E., Satake, H., Enzinger, P., Alsina, M., Benson, A., Chao, J., Ko, A. H., Wainberg, Z. A., Kher, U., Shah, S., Kang, S. P., & Tabernero, J. (2020). Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncology, 6(10), 1571-1580. https://doi.org/10.1001/jamaoncol.2020.3370
Shitara, K., Özgüroğlu, M., Bang, Y. J., Di Bartolomeo, M., Mandalà, M., Ryu, M. H., Fornaro, L., Olesiński, T., Caglevic, C., Chung, H. C., Muro, K., Goekkurt, E., Mansoor, W., McDermott, R. S., Shacham-Shmueli, E., Chen, X., Mayo, C., Kang, S. P., Ohtsu, A., & Fuchs, C. S. (2018). Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet, 392(10142), 123-133. https://doi.org/10.1016/s0140-6736(18)31257-1
Sikkema, M., de Jonge, P. J., Steyerberg, E. W., & Kuipers, E. J. (2010). Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 8(3), 235-244; quiz e232. https://doi.org/10.1016/j.cgh.2009.10.010
Singh, S., Singh, A. G., Singh, P. P., Murad, M. H., & Iyer, P. G. (2013). Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 11(6), 620-629. https://doi.org/10.1016/j.cgh.2012.12.036
Sjoquist, K. M., Burmeister, B. H., Smithers, B. M., Zalcberg, J. R., Simes, R. J., Barbour, A., & Gebski, V. (2011). Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. The Lancet. Oncology, 12(7), 681-692. https://doi.org/10.1016/s1470-2045(11)70142-5
Speicher, P. J., Ganapathi, A. M., Englum, B. R., Hartwig, M. G., Onaitis, M. W., D'Amico, T. A., & Berry, M. F. (2014). Induction therapy does not improve survival for clinical stage T2N0 esophageal cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 9(8), 1195-1201. https://doi.org/10.1097/JTO.0000000000000228
Stahl, M., Stuschke, M., Lehmann, N., Meyer, H. J., Walz, M. K., Seeber, S., Klump, B., Budach, W., Teichmann, R., Schmitt, M., Schmitt, G., Franke, C., & Wilke, H. (2005). Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23(10), 2310-2317. https://doi.org/10.1200/jco.2005.00.034
Stahl, M., Walz, M. K., Stuschke, M., Lehmann, N., Meyer, H. J., Riera-Knorrenschild, J., Langer, P., Engenhart-Cabillic, R., Bitzer, M., Konigsrainer, A., Budach, W., & Wilke, H. (2009). Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27(6), 851-856. https://doi.org/10.1200/jco.2008.17.0506
Steber, C., Hughes, R. T., McTyre, E. R., Soike, M., Farris, M., Levine, B. J., Pasche, B., Levine, E., & Blackstock, A. W. (2021). Cisplatin/5-Fluorouracil (5-FU) Versus Carboplatin/Paclitaxel Chemoradiotherapy as Definitive or Pre-Operative Treatment of Esophageal Cancer. Cureus, 13(1), e12574. https://doi.org/10.7759/cureus.12574
Stockeld, D., Tennvall, J., Wagenius, G., Albertsson, M., Backman, L., Brodin, O., Cwikiel, M., Granstrom, L., Gustafsson, G., Gustavsson, S., Hambraeus, G., Lewensohn, R., Sjostedt, S., Strander, H., Aberg, B., & Fagerberg, J. (2001). A Swedish study of chemoradiation in squamous cell carcinoma of the esophagus. Acta Oncol, 40(5), 566-573.
Sun, J. M., Shen, L., Shah, M. A., Enzinger, P., Adenis, A., Doi, T., Kojima, T., Metges, J. P., Li, Z., Kim, S. B., Cho, B. C., Mansoor, W., Li, S. H., Sunpaweravong, P., Maqueda, M. A., Goekkurt, E., Hara, H., Antunes, L., Fountzilas, C., Tsuji, A., Oliden, V. C., Liu, Q., Shah, S., Bhagia, P., & Kato, K. (2021). Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet, 398(10302), 759-771. https://doi.org/10.1016/s0140-6736(21)01234-4
Sun, L., & Yu, S. (2011). Meta-analysis: non-steroidal anti-inflammatory drug use and the risk of esophageal squamous cell carcinoma. Dis.Esophagus., 24(8), 544-549. https://doi.org/10.1111/j.1442-2050.2011.01198.x
Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. (2002). Lancet, 359(9319), 1727-1733.
Takeuchi, H., & Kitagawa, Y. (2019). Sentinel node navigation surgery in esophageal cancer. Ann Gastroenterol Surg, 3(1), 7-13. https://doi.org/10.1002/ags3.12206
Taurchini, M., & Cuttitta, A. (2017). Minimally invasive and robotic esophagectomy: state of the art. Journal of visualized surgery, 3, 125. https://doi.org/10.21037/jovs.2017.08.23
Ter Veer, E., Haj Mohammad, N., van Valkenhoef, G., Ngai, L. L., Mali, R. M. A., Anderegg, M. C., van Oijen, M. G. H., & van Laarhoven, H. W. M. (2016). The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis. Journal of the National Cancer Institute, 108(10), 10.1093/jnci/djw1166. https://doi.org/10.1093/jnci/djw166
Terheggen, G., Horn, E. M., Vieth, M., Gabbert, H., Enderle, M., Neugebauer, A., Schumacher, B., & Neuhaus, H. (2017). A randomised trial of endoscopic submucosal dissection versus endoscopic mucosal resection for early Barrett's neoplasia. Gut, 66(5), 783-793. https://doi.org/10.1136/gutjnl-2015-310126
Thuss-Patience, P. C., Kretzschmar, A., Bichev, D., Deist, T., Hinke, A., Breithaupt, K., Dogan, Y., Gebauer, B., Schumacher, G., & Reichardt, P. (2011). Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European journal of cancer (Oxford, England : 1990), 47(15), 2306-2314. https://doi.org/10.1016/j.ejca.2011.06.002
TNM Classification of malignant tumours. (2017). (8 utg.). Oxford,UK: Wiley-Blackwell.
Townsend, C. M. (2012). Sabiston textbook of surgery: the biological basis of modern surgical practice (19. utg.). Philadelphia, Pa.: Elsevier Saunders.
Tramacere, I., La Vecchia, C., & Negri, E. (2011). Tobacco smoking and esophageal and gastric cardia adenocarcinoma: a meta-analysis. Epidemiology (Cambridge, Mass.), 22(3), 344-349. https://doi.org/10.1097/EDE.0b013e31821092cd
Tramacere, I., Pelucchi, C., Bagnardi, V., Rota, M., Scotti, L., Islami, F., Corrao, G., Boffetta, P., La Vecchia, C., & Negri, E. (2012). A meta-analysis on alcohol drinking and esophageal and gastric cardia adenocarcinoma risk. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 23(2), 287-297. https://doi.org/10.1093/annonc/mdr136
Turati, F., Tramacere, I., La Vecchia, C., & Negri, E. (2013). A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 24(3), 609-617. https://doi.org/10.1093/annonc/mds244
Ulla, M., Gentile, E. M., Cavadas, D., Yeyati, E. L., Frank, L., Argerich, J. I., & Garcia Monaco, R. (2012). Esophageal cancer characterization with pneumo-64-MDCT. Abdominal imaging, 37(4), 501-511. https://doi.org/10.1007/s00261-011-9784-z
Van Cutsem, E., Boni, C., Tabernero, J., Massuti, B., Middleton, G., Dane, F., Reichardt, P., Pimentel, F. L., Cohn, A., Follana, P., Clemens, M., Zaniboni, A., Moiseyenko, V., Harrison, M., Richards, D. A., Prenen, H., Pernot, S., Ecstein-Fraisse, E., Hitier, S., & Rougier, P. (2015). Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 26(1), 149-156. https://doi.org/10.1093/annonc/mdu496
Van Cutsem, E., Moiseyenko, V. M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., Rodrigues, A., Fodor, M., Chao, Y., Voznyi, E., Risse, M. L., & Ajani, J. A. (2006). Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24(31), 4991-4997. https://doi.org/10.1200/jco.2006.06.8429
van Hagen, P., Hulshof, M. C., van Lanschot, J. J., Steyerberg, E. W., van Berge Henegouwen, M. I., Wijnhoven, B. P., Richel, D. J., Nieuwenhuijzen, G. A., Hospers, G. A., Bonenkamp, J. J., Cuesta, M. A., Blaisse, R. J., Busch, O. R., ten Kate, F. J., Creemers, G. J., Punt, C. J., Plukker, J. T., Verheul, H. M., Spillenaar Bilgen, E. J., van Dekken, H., van der Sangen, M. J., Rozema, T., Biermann, K., Beukema, J. C., Piet, A. H., van Rij, C. M., Reinders, J. G., Tilanus, H. W., & van der Gaast, A. (2012). Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med, 366(22), 2074-2084. https://doi.org/10.1056/NEJMoa1112088
van Meerten, E., Muller, K., Tilanus, H. W., Siersema, P. D., Eijkenboom, W. M., van Dekken, H., Tran, T. C., & van der Gaast, A. (2006). Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study. Br J Cancer, 94(10), 1389-1394.
van Rijswijk, A. S., Hagens, E. R. C., van der Peet, D. L., van Berge Henegouwen, M. I., & Gisbertz, S. S. (2019). Differences in Esophageal Cancer Surgery in Terms of Surgical Approach and Extent of Lymphadenectomy: Findings of an International Survey. Ann Surg Oncol, 26(7), 2063-2072. https://doi.org/10.1245/s10434-019-07316-9
van Rossum, P. S., van Lier, A. L., Lips, I. M., Meijer, G. J., Reerink, O., van Vulpen, M., Lam, M. G., van Hillegersberg, R., & Ruurda, J. P. (2015). Imaging of oesophageal cancer with FDG-PET/CT and MRI. Clinical radiology, 70(1), 81-95. https://doi.org/10.1016/j.crad.2014.07.017
van Ruler, M. A., Peters, F. P., Slingerland, M., Fiocco, M., Grootenboers, D. A., Vulink, A. J., Marijnen, C. A., & Neelis, K. J. (2017). Clinical outcomes of definitive chemoradiotherapy using carboplatin and paclitaxel in esophageal cancer. Dis.Esophagus., 30(4), 1-9. https://doi.org/10.1093/dote/dow033
van Ruler, M. A. P., Peters, F. P., Slingerland, M., Fiocco, M., Grootenboers, D. A. R. H., Vulink, A. J. E., Marijnen, C. A. M., & Neelis, K. J. (2017). Clinical outcomes of definitive chemoradiotherapy using carboplatin and paclitaxel in esophageal cancer. Dis.Esophagus., 30(4), 1-9. https://doi.org/10.1093/dote/dow033
van Workum, F., Klarenbeek, B. R., Baranov, N., Rovers, M. M., & Rosman, C. (2020). Totally minimally invasive esophagectomy versus hybrid minimally invasive esophagectomy: systematic review and meta-analysis. Dis.Esophagus., 33(8). https://doi.org/10.1093/dote/doaa021
Visser, E., Markar, S. R., Ruurda, J. P., Hanna, G. B., & van Hillegersberg, R. (2019). Prognostic Value of Lymph Node Yield on Overall Survival in Esophageal Cancer Patients: A Systematic Review and Meta-analysis. Ann Surg., 269(2), 261-268. https://doi.org/10.1097/sla.0000000000002824
von Döbeln, G. A., Klevebro, F., Jacobsen, A. B., Johannessen, H. O., Nielsen, N. H., Johnsen, G., Hatlevoll, I., Glenjen, N. I., Friesland, S., Lundell, L., Yu, J., & Nilsson, M. (2019). Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial. Dis.Esophagus., 32(2), 10.1093/dote/doy1078. https://doi.org/10.1093/dote/doy078
Wagner, A. D., Syn, N. L., Moehler, M., Grothe, W., Yong, W. P., Tai, B.-C., Ho, J., & Unverzagt, S. (2017). Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev., 8(8), CD004064. https://doi.org/10.1002/14651858.CD004064.pub4
Walterbos, N. R., Fiocco, M., Neelis, K. J., van der Linden, Y. M., Langers, A. M. J., Slingerland, M., de Steur, W. O., Peters, F. P., & Lips, I. M. (2019). Effectiveness of several external beam radiotherapy schedules for palliation of esophageal cancer. Clinical and Translational Radiation Oncology, 17, 24-31. https://doi.org/10.1016/j.ctro.2019.04.017
Wang, Z., Mao, Y., Gao, S., Li, Y., Tan, L., Daiko, H., Liu, S., Chen, C., Koyanagi, K., & He, J. (2020). Lymph node dissection and recurrent laryngeal nerve protection in minimally invasive esophagectomy. Annals of the New York Academy of Sciences, 1481(1), 20-29. https://doi.org/10.1111/nyas.14427
Webb, A., Cunningham, D., Scarffe, J. H., Harper, P., Norman, A., Joffe, J. K., Hughes, M., Mansi, J., Findlay, M., Hill, A., Oates, J., Nicolson, M., Hickish, T., O'Brien, M., Iveson, T., Watson, M., Underhill, C., Wardley, A., & Meehan, M. (1997). Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 15(1), 261-267. https://doi.org/10.1200/JCO.1997.15.1.261
Weimann, A., Braga, M., Harsanyi, L., Laviano, A., Ljungqvist, O., Soeters, P., Jauch, K. W., Kemen, M., Hiesmayr, J. M., Horbach, T., Kuse, E. R., & Vestweber, K. H. (2006). ESPEN Guidelines on Enteral Nutrition: Surgery including organ transplantation. Clin Nutr., 25(2), 224-244.
Welsh, J., Settle, S. H., Amini, A., Xiao, L., Suzuki, A., Hayashi, Y., Hofstetter, W., Komaki, R., Liao, Z., & Ajani, J. A. (2012). Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer, 118(10), 2632-2640. https://doi.org/10.1002/cncr.26586
Wenger, U., Luo, J., Lundell, L., & Lagergren, J. (2005). A nationwide study of the use of self-expanding stents in patients with esophageal cancer in Sweden. Endoscopy, 37(4), 329-334.
Weusten, B., Bisschops, R., Coron, E., Dinis-Ribeiro, M., Dumonceau, J. M., Esteban, J. M., Hassan, C., Pech, O., Repici, A., Bergman, J., & di Pietro, M. (2017). Endoscopic management of Barrett's esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy, 49(2), 191-198. https://doi.org/10.1055/s-0042-122140
Wilke, H., Muro, K., Van Cutsem, E., Oh, S. C., Bodoky, G., Shimada, Y., Hironaka, S., Sugimoto, N., Lipatov, O., Kim, T. Y., Cunningham, D., Rougier, P., Komatsu, Y., Ajani, J., Emig, M., Carlesi, R., Ferry, D., Chandrawansa, K., Schwartz, J. D., & Ohtsu, A. (2014). Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. The Lancet. Oncology, 15(11), 1224-1235. https://doi.org/10.1016/s1470-2045(14)70420-6
Winiker, M., Mantziari, S., Figueiredo, S. G., Demartines, N., Allemann, P., & Schafer, M. (2018). Accuracy of preoperative staging for a priori resectable esophageal cancer. Dis.Esophagus., 31(1), 1-6. https://doi.org/10.1093/dote/dox113
World Cancer Research Fund/American Institute for Cancer Research. (2018a). Diet, Nutrition, Physical Activity and Cancer: a Global Perspective:a summary of the Third Expert Report (Continous Update Project Expert Report 2018). London: World Cancer Research Fund/American Institute for Cancer Research. Hentet fra https://www.wcrf.org/wp-content/uploads/2021/02/Summary-of-Third-Expert-Report-2018.pdf
World Cancer Research Fund/American Institute for Cancer Research. (2018b). Diet, nutrition, physical and oesophageal cancer (Continuous Update Project Expert Report 2018). London. Hentet fra https://www.wcrf.org/wp-content/uploads/2021/02/oesophageal-cancer-report.pdf
Wu, A. H., Wan, P., & Bernstein, L. (2001). A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States). Cancer causes & control : CCC, 12(8), 721-732.
Wullstein, C., Ro-Papanikolaou, H. Y., Klingebiel, C., Ersahin, K., & Carolus, R. (2015). Minimally Invasive Techniques and Hybrid Operations for Esophageal Cancer. Viszeralmedizin, 31(5), 331-336. https://doi.org/10.1159/000438661
Wyss, A., Hashibe, M., Chuang, S. C., Lee, Y. C., Zhang, Z. F., Yu, G. P., Winn, D. M., Wei, Q., Talamini, R., Szeszenia-Dabrowska, N., Sturgis, E. M., Smith, E., Shangina, O., Schwartz, S. M., Schantz, S., Rudnai, P., Purdue, M. P., Eluf-Neto, J., Muscat, J., Morgenstern, H., Michaluart, P., Jr., Menezes, A., Matos, E., Mates, I. N., Lissowska, J., Levi, F., Lazarus, P., La Vecchia, C., Koifman, S., Herrero, R., Hayes, R. B., Franceschi, S., Wunsch-Filho, V., Fernandez, L., Fabianova, E., Daudt, A. W., Dal Maso, L., Curado, M. P., Chen, C., Castellsague, X., de Carvalho, M. B., Cadoni, G., Boccia, S., Brennan, P., Boffetta, P., & Olshan, A. F. (2013). Cigarette, cigar, and pipe smoking and the risk of head and neck cancers: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. American journal of epidemiology, 178(5), 679-690. https://doi.org/10.1093/aje/kwt029
Xu, Y., Yu, X., Chen, Q., & Mao, W. (2012). Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma? World journal of surgical oncology, 10, 173. https://doi.org/10.1186/1477-7819-10-173
Xu, Y. J., Zhu, W. G., Liao, Z. X., Kong, Y., Wang, W. W., Li, J. C., Huang, R., He, H., Yang, X. M., Liu, L. P., Sun, Z. W., He, H. J., Bao, Y., Zeng, M., Pu, J., Hu, W. Y., Ma, J., Jiang, H., Liu, Z. G., Zhuang, T. T., Tan, B. X., Du, X. H., Qiu, G. Q., Zhou, X., Ji, Y. L., Hu, X., Wang, J., Ma, H. L., Zheng, X., Huang, J., Liu, A. W., Liang, X. D., Tao, H., Zhou, J. Y., Liu, Y., & Chen, M. (2020). [A multicenter randomized prospective study of concurrent chemoradiation with 60 Gy versus 50 Gy for inoperable esophageal squamous cell carcinoma]. Zhonghua Yi Xue Za Zhi, 100(23), 1783-1788. https://doi.org/10.3760/cma.j.cn112137-20200303-00574
Yamamoto, S., Kawakami, H., Kii, T., Hara, H., Kawabata, R., Kawada, J., Takeno, A., Matsuyama, J., Ueda, S., Okita, Y., Endo, S., Kimura, Y., Yanagihara, K., Okuno, T., Kurokawa, Y., Shimokawa, T., & Satoh, T. (2021). Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory to fluoropyrimidine- and platinum-based chemotherapy: OGSG1201. European journal of cancer (Oxford, England : 1990), 154, 307-315. https://doi.org/10.1016/j.ejca.2021.06.035
Yerokun, B. A., Sun, Z., Yang, C. J., Gulack, B. C., Speicher, P. J., Adam, M. A., D'Amico, T. A., Onaitis, M. W., Harpole, D. H., Berry, M. F., & Hartwig, M. G. (2016). Minimally Invasive Versus Open Esophagectomy for Esophageal Cancer: A Population-Based Analysis. The Annals of thoracic surgery, 102(2), 416-423. https://doi.org/10.1016/j.athoracsur.2016.02.078
Yuan, L. G., & Mao, Y. S. (2019). Thoracic recurrent laryngeal nerve lymph node metastasis guides the cervical lymph node dissection of patients with esophageal cancer. Zhonghua Zhong Liu Za Zhi, 41(1), 10-14. https://doi.org/10.3760/cma.j.issn.0253-3766.2019.01.003
Zenda, S., Kojima, T., Kato, K., Izumi, S., Ozawa, T., Kiyota, N., Katada, C., Tsushima, T., Ito, Y., Akimoto, T., Hasegawa, Y., Kanamaru, M., & Daiko, H. (2016). Multicenter Phase 2 Study of Cisplatin and 5-Fluorouracil With Concurrent Radiation Therapy as an Organ Preservation Approach in Patients With Squamous Cell Carcinoma of the Cervical Esophagus. International journal of radiation oncology, biology, physics, 96(5), 976-984. https://doi.org/10.1016/j.ijrobp.2016.08.045
Zhang, Y. (2013). Epidemiology of esophageal cancer. World journal of gastroenterology, 19(34), 5598-5606. https://doi.org/10.3748/wjg.v19.i34.5598
Zhang, Z., Liao, Z., Jin, J., Ajani, J., Chang, J. Y., Jeter, M., Guerrero, T., Stevens, C. W., Swisher, S., Ho, L., Yao, J., Allen, P., Cox, J. D., & Komaki, R. (2005). Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. International journal of radiation oncology, biology, physics, 61(3), 656-664. https://doi.org/10.1016/j.ijrobp.2004.06.022
Zheng, R., Rios-Diaz, A. J., Liem, S., Devin, C. L., Evans, N. R., 3rd, Rosato, E. L., Palazzo, F., & Berger, A. C. (2021). Is the placement of jejunostomy tubes in patients with esophageal cancer undergoing esophagectomy associated with increased inpatient healthcare utilization? An analysis of the National Readmissions Database. Am J Surg., 221(1), 141-148. https://doi.org/10.1016/j.amjsurg.2020.06.028
Zhou, H.-Y., Zheng, S.-P., Li, A.-L., Gao, Q.-L., Ou, Q.-Y., Chen, Y.-J., Wu, S.-T., Lin, D.-G., Liu, S.-B., Huang, L.-Y., Li, F.-S., Zhu, H.-Y., Qiao, G.-B., Lanuti, M., Yao, H.-R., & Yu, Y.-F. (2020). Clinical evidence for association of neoadjuvant chemotherapy or chemoradiotherapy with efficacy and safety in patients with resectable esophageal carcinoma (NewEC study). EClinicalMedicine, 24, 100422. https://doi.org/10.1016/j.eclinm.2020.100422